Latest News and Press Releases

– Multi-target agreement positions Stipple Bio to advance next-generation ADC therapies using Lonza’s clinically validated ADC platform — — Stipple Bio’s Pointillist Platform identifies...

Agios announces an agreement with Oscotec to license the exclusive global rights to cevidoplenib, a novel, next generation, oral SYK inhibitor

Orelabrutinib (HIBRUKA®) has been approved by TGA in Australia, offering a new treatment option for patients with R/R MCL in the region.

London, May 26, 2026 (GLOBE NEWSWIRE) -- Gordon Brothers, the global asset experts, has acquired the Radley brand and related intellectual property. As the new brand owner, the firm will drive a...

SKYX Signs a Licensing Agreement for Its Advanced Technologies with U.S., Canada, and Global Leading Lighting Company Eurofase

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002 to Jupiter Neurosciences in a Transaction Valued at Over $100 Million USD

BRUXELLES, 20 mai 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, ci-après « SERB », et Hansa Biopharma AB, ci-après « Hansa » (Nasdaq Stockholm : HNSA) annoncent la conclusion d’un accord portant...

BRÜSSEL, May 20, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals („SERB“) und Hansa Biopharma AB („Hansa“) (Nasdaq Stockholm: HNSA) gaben heute bekannt, dass sie eine Vereinbarung getroffen...

WILMINGTON, Del., May 19, 2026 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a wireless, video, and AI technology research and development company, today announced that the company has...

SERB Pharmaceuticals to acquire development and commercialisation rights to Idefirix® (imlifidase) in Europe and MENA from Hansa Biopharma for €115 million